STOCK TITAN

PRESSURE BIOSCIENCES - PBIO STOCK NEWS

Welcome to our dedicated page for PRESSURE BIOSCIENCES news (Ticker: PBIO), a resource for investors and traders seeking the latest updates and insights on PRESSURE BIOSCIENCES stock.

Pressure BioSciences, Inc. (PBIO) is a forefront life sciences company that focuses on the development and commercialization of an innovative platform technology known as Pressure Cycling Technology (PCT). This technology employs cycles of hydrostatic pressure, ranging from ambient to ultra-high levels (up to 35,000 psi and beyond), to precisely control biomolecular interactions, offering significant advancements in various scientific fields.

The company's core business revolves around leveraging PCT to enhance the analysis, study, and manipulation of biological samples. This technology has broad applications in areas such as protein characterization, pathogen inactivation, and the preparation of samples for genomic and proteomic studies. By utilizing PCT, researchers and scientists can achieve higher yields, improved quality, and better consistency in their biological analyses.

Recently, PBIO has made notable strides with the introduction of its new consumer products business unit, Uncle Bud’s. In January 2024, the company kicked off with a substantial $252,000 shipment of its Sunburn Soother to one of the world’s largest retailers, showcasing strong market demand and consumer interest. Additionally, VICAR Holdings LLC has committed to purchasing over 10,000 bottles of PBIO's best-in-class Nano-CBD topical spray in 2024, indicating a promising trajectory for their consumer products segment.

PBIO's relocation to a new facility has significantly increased their manufacturing space, enhanced operating efficiencies, and achieved measurable cost savings, setting the stage for unencumbered growth through multi-year expansion plans. The new facility is expected to support the company's long-term strategy and scale operations to meet growing demand.

Uncle Bud's acquisition has already yielded early synergies and measurable performance metrics within the first month, boosting PBIO's market presence and consumer engagement. This positive momentum highlights PBIO's capability to integrate and scale operations effectively.

Furthermore, Pressure BioSciences’ UltraShear platform continues to showcase its potential by enabling the development and launch of health and wellness products with groundbreaking bioavailability, fast onset, and effectiveness. This platform technology is a testament to PBIO's commitment to innovation and enhancing the quality and effectiveness of bio-molecular research and consumer applications.

Rhea-AI Summary
Pressure BioSciences (PBIO) scientists, in collaboration with Lonza Biologics, presented their patented BaroFoldTM platform for biomanufacturing protein drugs. The platform demonstrated breakthrough efficiency and economics compared to current methods, with potential to revolutionize protein therapeutics production. The global protein therapeutics market is expected to reach $488 billion by 2030. PBIO estimates that BaroFold Manufacturing Systems could generate several million dollars in contracts and eventually exceed $100M in annual revenue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.49%
Tags
none
-
Rhea-AI Summary
Pressure BioSciences announces partnership with Bioscreen Instruments for distribution agreement in India's pharmaceutical industry
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
55.42%
Tags
none
-
Rhea-AI Summary
Pressure BioSciences (PBIO) receives Canadian patent for UltraShear Technology platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
none
Rhea-AI Summary
PBIO acknowledges emerging demand potential for UltraShear nanoemulsions, increases purchase order with VST by 10-fold
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
none
-
Rhea-AI Summary
Pressure BioSciences announces completion of manufacturing capacity expansion and receipt of backorders for Nano-CBD processing. Initial shipments to begin in October. Expectation of continued growth in new orders throughout Q4 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.17%
Tags
none
-
Rhea-AI Summary
Pressure BioSciences announces transition in collaborations with biopharmaceutical leaders, expects BaroFold platform to generate over $100M in annual revenue
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
Rhea-AI Summary
PBIO receives commitments from five new distributors for their Nano-CBD product, expected to generate $200K to $250K in incremental 2023 sales. The distributors represent over 345 dispensaries, with anticipated reorders to further increase revenues. PBIO's 'Drive to 420' program aims to access 420 retail outlets within the first month of launch. UltraShear technology platform has transformative impact on multiple multi-billion dollar markets. PBIO has dedicated resources to accelerate the development and commercialization of UltraShear.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
-
Rhea-AI Summary
Pressure BioSciences reports Q2 2023 financial results, with total revenue of $511,800, a 3% increase from Q2 2022. Instrument/Consumable sales increased by 13% to $445,500. Operating loss increased by 20% to $1,081,500. Cash Used from Operations decreased by 27% to $899,200. Q2 2023 diluted net loss per share was $(0.57), compared to $(0.32) in Q2 2022. 1st Half 2023 total revenue increased by 28% to $1,252,403. Operating loss for 1st Half 2023 was $4,719,200, compared to $1,987,900 in 1st Half 2022. Cash Used from Operations in 1st Half 2023 decreased by 34% to $1,321,400. 1st Half 2023 diluted net loss per share was $(1.03), compared to $(0.80) in 1st Half 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.91%
Tags
-
Rhea-AI Summary
Pressure BioSciences Inc. (PBIO) announced that its President and CEO, Richard T. Schumacher, and Director of Marketing & Sales, John B. Hollister, will be the featured speakers at an online webinar titled 'Health and Wellness Innovations: The Marvels of UltraShear™' on August 17, 2023, at 11:00AM ET. The webinar aims to provide an overview of PBIO's core technologies and products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.9%
Tags
conferences
Rhea-AI Summary
Pressure BioSciences, Inc. (PBIO) has added five new U.S. distributors and secured initial market-seeding orders for over $300,000 of its UltraShear Nano-CBD topical spray product. The company expects substantial subsequent orders throughout 2023. UltraShear Nano-CBD offers powerful product performance differentiation with its unique uniform and ultra-low nano-droplet sizes of hemp-derived CBD oil in water. The company anticipates imminent publication of research highlighting the superior absorption and bioavailability of its product compared to current CBD formulations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
none

FAQ

What is the current stock price of PRESSURE BIOSCIENCES (PBIO)?

The current stock price of PRESSURE BIOSCIENCES (PBIO) is $0.0025 as of December 23, 2024.

What is the market cap of PRESSURE BIOSCIENCES (PBIO)?

The market cap of PRESSURE BIOSCIENCES (PBIO) is approximately 82.2K.

What is Pressure BioSciences, Inc. (PBIO)?

Pressure BioSciences, Inc. (PBIO) is a life sciences company focused on developing and commercializing Pressure Cycling Technology (PCT) to control biomolecular interactions.

What is Pressure Cycling Technology (PCT)?

PCT is a platform technology that uses cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions.

In which areas is PCT technology applied?

PCT technology is applied in protein characterization, pathogen inactivation, and the preparation of samples for genomic and proteomic studies.

What recent achievements has PBIO made?

PBIO recently shipped $252,000 of its Sunburn Soother to a major retailer and secured a purchase order for over 10,000 bottles of Nano-CBD topical spray from VICAR Holdings LLC.

What is Uncle Bud’s?

Uncle Bud’s is PBIO's new consumer products business unit, focusing on health and wellness products such as the Nano-CBD topical spray.

How has PBIO's new facility impacted the company?

The new facility has increased manufacturing space, improved operating efficiencies, and achieved cost savings, supporting PBIO's long-term growth plans.

What is the UltraShear platform?

The UltraShear platform enables the development and launch of health and wellness products with revolutionary bioavailability, fast onset, and effectiveness.

How has Uncle Bud’s performed since its acquisition?

Uncle Bud’s has reported early synergies and measurable performance metrics within the first month, enhancing PBIO's market presence and consumer engagement.

What are some applications of PBIO’s products?

PBIO’s products are used in scientific research for protein analysis, pathogen inactivation, and preparation of biological samples for various studies.

What is the significance of PBIO’s consumer products?

PBIO’s consumer products, such as the Nano-CBD topical spray, offer advanced bioavailability and effectiveness, reflecting the company's innovation in health and wellness.

PRESSURE BIOSCIENCES

OTC:PBIO

PBIO Rankings

PBIO Stock Data

82.23k
37.04M
0.9%
2.38%
Medical Devices
Healthcare
Link
United States of America
Canton